Toledo, Ohio — January 8, 2026 — NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, announced the completion of a strategic acquisition of select assets from the Early Development medical device testing business of Labcorp. The transaction transfers Labcorp’s U.S.-based early-stage device testing portfolio to NAMSA, significantly expanding its end-to-end MedTech development capabilities and reinforcing its mission to accelerate innovation and reduce time-to-market for medical device manufacturers worldwide.
Science Significance
From a scientific standpoint, the acquisition strengthens NAMSA’s ability to support rigorous preclinical evaluation of medical devices across a broad range of technologies and therapeutic areas. The acquired assets include biocompatibility testing, microbiological testing, analytical chemistry, and preclinical research services, all of which are foundational to demonstrating device safety and performance. By integrating these capabilities into its existing scientific infrastructure, NAMSA enhances the continuity and depth of early development testing, enabling more consistent data generation and interpretation. This consolidation supports higher-quality translational science, allowing device developers to move more efficiently from concept through preclinical validation and into clinical investigation.
Regulatory Significance
Regulatory readiness is a critical determinant of MedTech success, and the transaction carries substantial regulatory implications. The acquired testing services play a central role in supporting FDA, EU MDR, and global regulatory submissions, particularly for biocompatibility and preclinical safety packages. By bringing these services fully in-house, NAMSA can offer greater integration between testing, clinical strategy, and regulatory consulting, reducing fragmentation that often complicates regulatory reviews. The move strengthens NAMSA’s ability to deliver compliance-driven, inspection-ready data aligned with evolving global standards, helping sponsors navigate increasingly complex regulatory expectations with greater confidence and predictability.
Business Significance
Advertisement
Strategically, the acquisition represents a significant expansion of NAMSA’s service portfolio and market leadership. By assuming Labcorp’s U.S. early development medical device testing operations, NAMSA deepens its presence across the most critical stages of the device lifecycle and broadens access to specialized expertise. The deal also aligns with NAMSA’s long-term growth strategy under its ownership by ARCHIMED, marking the company’s 10th acquisition since 2020. For Labcorp, the divestiture allows sharper focus on core areas of preclinical drug development and chemical testing, while ensuring continuity of service for device-focused clients through a specialized partner.
Patients’ Significance
Although the transaction is business-to-business in nature, the downstream impact for patients is meaningful. More efficient and integrated medical device testing can shorten development timelines, reduce late-stage failures, and improve the overall quality of evidence supporting device safety and performance. By accelerating the pathway from early testing to clinical use, the expanded NAMSA platform ultimately supports faster access to innovative medical technologies, from diagnostic tools to implantable and therapeutic devices. Improved development efficiency also contributes to higher-quality devices entering the healthcare system, enhancing patient safety and clinical outcomes.
Policy Significance
At the policy level, the acquisition reflects broader trends toward specialization, consolidation, and compliance-focused service delivery in the MedTech ecosystem. As regulators place increasing emphasis on robust preclinical evidence, traceability, and lifecycle oversight, specialized organizations with integrated testing and regulatory expertise are becoming essential partners for innovation. The transaction aligns with policy objectives that encourage high standards of safety, scientific rigor, and regulatory accountability, while supporting the scalability needed to meet global healthcare demands. It also highlights the role of private investment in strengthening critical healthcare infrastructure.
With the acquisition of Labcorp’s Early Development medical device testing assets, NAMSA further cements its position as a comprehensive innovation partner for MedTech manufacturers, offering integrated testing, clinical, and regulatory solutions across the product lifecycle. As medical device development becomes more complex and regulatory scrutiny intensifies, this strategic move positions NAMSA to deliver greater scientific depth, regulatory confidence, and operational efficiency. The transaction not only reshapes the competitive landscape for MedTech services but also reinforces a shared industry commitment to advancing safe, effective, and timely medical technologies.
Source: NAMSA press release
